Related references
Note: Only part of the references are listed.Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases
Andrew Snavely et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)
Multiple sclerosis outcomes after cancer immunotherapy
Catherine R. Garcia et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer
Marzia Anita Lucia Romeo et al.
JOURNAL OF NEUROLOGY (2019)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neurological complications of immune checkpoint inhibitors: what happens when you take the brakes off' the immune system
Marinos C. Dalakas
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
P04.07 Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab
L. Gómez Vicente et al.
NEURO-ONCOLOGY (2017)
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
D. Makarious et al.
EUROPEAN JOURNAL OF CANCER (2017)
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis
Lisa Ann Gerdes et al.
ANNALS OF NEUROLOGY (2016)
CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment
Yonghao Cao et al.
NEUROLOGY (2016)
Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
Edward J. Gettings et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Share Paper
